MX362193B - Composicion farmaceutica para administracion oral. - Google Patents

Composicion farmaceutica para administracion oral.

Info

Publication number
MX362193B
MX362193B MX2016017402A MX2016017402A MX362193B MX 362193 B MX362193 B MX 362193B MX 2016017402 A MX2016017402 A MX 2016017402A MX 2016017402 A MX2016017402 A MX 2016017402A MX 362193 B MX362193 B MX 362193B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
oral administration
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2016017402A
Other languages
English (en)
Other versions
MX2016017402A (es
Inventor
Kojima Hiroyuki
Miyazaki Masajazu
Nishiura Mare
Nishizato Takashi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2016017402A publication Critical patent/MX2016017402A/es
Publication of MX362193B publication Critical patent/MX362193B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una composición farmacéutica para administración oral que proporciona reducción de tamaño y solubilidad mejorada, propiedades de disolución mejoradas y capacidad de absorción mejorada de amida (2R)-N-({5-[3-(2,5-difluorofenil)-2-(1,3-dihidro -2H-bencimidazol-2-ilideno)-3-oxopropanoil]-2-fluorofenil}sulfoni l)-2-hidroxipropanoimida (de aquí en adelante denominado como compuesto A) o una sal farmacéuticamente aceptable de la misma. La composición farmacéutica para administración oral contiene un polìmero o una forma amorfa del compuesto A o su sal farmacéuticamente aceptable.
MX2016017402A 2014-06-24 2015-06-24 Composicion farmaceutica para administracion oral. MX362193B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014129374 2014-06-24
PCT/JP2015/068139 WO2015199115A1 (ja) 2014-06-24 2015-06-24 経口投与用医薬組成物

Publications (2)

Publication Number Publication Date
MX2016017402A MX2016017402A (es) 2017-05-01
MX362193B true MX362193B (es) 2019-01-08

Family

ID=54938194

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017402A MX362193B (es) 2014-06-24 2015-06-24 Composicion farmaceutica para administracion oral.

Country Status (9)

Country Link
US (1) US9775832B2 (es)
EP (1) EP3162368A4 (es)
JP (1) JPWO2015199115A1 (es)
CN (1) CN106456612A (es)
HK (1) HK1232144A1 (es)
MX (1) MX362193B (es)
PH (1) PH12016502285A1 (es)
TW (1) TW201613579A (es)
WO (1) WO2015199115A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3318259T3 (fi) 2015-07-03 2023-03-20 Astellas Pharma Inc Stabiili farmaseuttinen koostumus annettavaksi suun kautta
MX2020001877A (es) * 2017-08-18 2020-09-14 Abbvie Inc Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS5948810B2 (ja) 1980-03-22 1984-11-29 山之内製薬株式会社 ニカルジピン持続性製剤用組成物
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
SI1864976T1 (sl) 2005-03-31 2012-12-31 Astellas Pharma Inc. Propan-1,3-dionski derivat ali njegova sol
JP5517327B2 (ja) * 2008-12-16 2014-06-11 日医工株式会社 口腔内崩壊錠用組成物
CN103687596B (zh) * 2011-04-22 2016-08-17 安斯泰来制药有限公司 固态医药组合物
JP2013180961A (ja) * 2012-02-29 2013-09-12 Astellas Pharma Inc Ｗｓ７２７７１３含有固形製剤
KR20150048762A (ko) 2012-09-07 2015-05-07 아스텔라스세이야쿠 가부시키가이샤 술포닐아미딘 화합물의 제조법
JP2014051470A (ja) * 2012-09-07 2014-03-20 Astellas Pharma Inc スルホニルアミジン化合物の結晶

Also Published As

Publication number Publication date
MX2016017402A (es) 2017-05-01
TW201613579A (en) 2016-04-16
EP3162368A4 (en) 2018-03-07
US20170143678A1 (en) 2017-05-25
US9775832B2 (en) 2017-10-03
PH12016502285A1 (en) 2017-02-13
JPWO2015199115A1 (ja) 2017-04-20
CN106456612A (zh) 2017-02-22
WO2015199115A1 (ja) 2015-12-30
HK1232144A1 (zh) 2018-01-05
EP3162368A1 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
MX2021014509A (es) Composiciones farmaceuticas que comprenden meloxicam.
MY199007A (en) Pharmaceutical compositions comprising meloxicam
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
MY183536A (en) Pharmaceutical compositions comprising azd9291
EP4650374A3 (en) Pharmaceutical compositions comprising meloxicam
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
PH12016500170A1 (en) Formulation of syk inhibitors
MX394588B (es) Composición farmacéutica.
EP4201399A3 (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
CL2017001479A1 (es) Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
PH12017502252B1 (en) Stable pharmaceutical composition for oral administration
EA201692298A1 (ru) Производные карбоксамидов
MX2017013896A (es) Composicion farmaceutica para administracion oral.
PH12016502285A1 (en) Pharmaceutical composition for oral administration
MY175971A (en) Heterocyclic acetamide compound
PH12016502527A1 (en) Stabilized desmopressin
NZ731220A (en) Methods for treating kidney disorders
TH167761A (th) องค์ประกอบทางเภสัชกรรมสำหรับให้ทางปาก
MY203481A (en) Pharmaceutical compositions comprising meloxicam
UA91650U (uk) Фармацевтична композиція похідних гамма-аміномасляної кислоти для твердих капсул

Legal Events

Date Code Title Description
FG Grant or registration